News

3 min read

Causaly, Microsoft link computation and scientific reasoning

The workflow aims to help biopharma teams assess targets, biomarkers, safety and mechanism questions with cited evidence.

June 29, 2026

Causaly, Microsoft link computation and scientific reasoning

Causaly announced a collaboration with Microsoft at Microsoft Build 2026 that brings scientific computation and scientific interpretation together into a single, evidence-grounded workflow for life sciences R&D. The solution combines Microsoft Discovery‘s enterprise-scale analytics, prediction, and simulation with Causaly’s knowledge-graph reasoning across internal and external scientific sources. Together, they move R&D teams from computational signal to cited, defensible decisions without leaving a governed environment.

Read the full announcement on Engineering.com

More news

Microsoft and Causaly Integration Accelerates Biopharma R&D Through AI-Driven Scientific Reasoning

The technical significance of this integration lies in its ability to move beyond simple ‘horizontal’ AI tools.

Causaly and Microsoft target one of drug discovery’s most expensive decisions: which target to pursue

What compresses is the knowledge work, the analytical layer that sits on a program’s critical path: building a baseline of what’s known, drafting protocols, reviewing safety, selecting candidates.

Causaly and Microsoft Collaborate to Connect Scientific Computation to Scientific Decision-Making for Life Sciences R&D

Helping R&D teams move from raw internal data to cited, defensible scientific decisions in a single governed workflow —setting a new standard for speed, rigor, and provenance in drug discovery and development

Causaly Introduces Scientific Workflows to Turn Expert Scientific Methods into Repeatable, AI-Executed Processes in Life Sciences

Causaly platform codifies biopharma R&D processes into end-to-end workflows that AI agents run consistently for any program, team, and therapeutic area

The Medicine Maker: Why Copilots Failed in R&D and What Comes Next

As featured in The Medicine Maker

Organizations that benefit most from AI in R&D will be those that align technology with scientific reality

How Agentic AI Learns to Think Like a Scientist

January 14, 2026

What happens when AI stops guessing and starts reasoning? Agentic AI is bringing scientific logic into the heart of drug discovery.

Causaly Launches Agentic AI Platform to Transform Life Sciences R&D

October 9, 2025

Causaly has unveiled Causaly Agentic Research, a breakthrough agentic AI platform purpose-built for life sciences research and development.

Causaly Introduces First Agentic AI Platform Built for Life Sciences Research and Development

September 16, 2025

Specialized AI agents automate research workflows and accelerate drug discovery and development with transparent, evidence-backed insights

Causaly Launches AI-powered Competitive Intelligence Application for Research Scientists

New Pipeline Graph unifies competitive insights with preclinical research on a single AI platform to accelerate drug target identification and increase commercial success

Causaly Announces Agentic AI for Scientific Discovery

New AI agents in Causaly Discover empower scientists to answer complex biomedical questions faster and more accurately across a broader range of sources

How generative AI is transforming early Drug Discovery: Insights from Novartis’ Jeremy Jenkins at Hariri Institute, Boston

November 7, 2024

Keynote Spotlight: Jeremy Jenkins on Generative AI in Early Drug Discovery

Causaly Raises $60 Million in Series B Funding to Catalyze AI-powered Preclinical Discovery

The financing, led by ICONIQ Growth, enables Causaly to accelerate innovation and drive increased adoption of its category-leading AI platform to modernize scientific research.

Causaly announces ISO 27001 certification

We are proud to announce a major milestone for Causaly: successfully passing ISO 27001 certification.

Causaly raises $17 million to accelerate biomedical research and discovery of scientific breakthroughs

Yiannis Kiachopoulos

Causaly, the London-based company that allows researchers and specialists to intuitively map and navigate the intricate landscape of biomedical research, has raised $17 million from investors to grow its team and expand into new markets.

Covid-19: Causaly partners with UCL to accelerate coronavirus research

Yiannis Kiachopoulos

At Causaly we’re excited to announce a new partnership with University College London (UCL) to help accelerate research into the pandemic.

Causaly raises $5m in Series A round led by Pentech Ventures

Yiannis Kiachopoulos

November 19, 2019

Causaly, the AI company that is teaching computers to read, understand and interpret all biomedical knowledge ever published, is pleased to announce its series A funding round, which saw new and existing investors commit $4.8m into the company. Pentech Ventures led the round together with EBRD Venture Capital, with participation from existing investors Marathon Venture Capital as well as existing angel investors.

Get started with Causaly

Ready to transform the way your R&D teams discover and deliver? Take the first step - see Causaly for yourself.